New Guidance Tackles Australian Post-Market Review Worries
This article was originally published in PharmAsia News
Executive Summary
A new version of the Australian framework for post-market reviews, which are used to monitor marketed medicines in order to improve the quality of their use and help ensure the sustainability of the Pharmaceutical Benefits Scheme, is expected to be published soon following its adoption by the government and the pharmaceutical industry.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.